[go: up one dir, main page]

BRPI0519096A2 - Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez - Google Patents

Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez

Info

Publication number
BRPI0519096A2
BRPI0519096A2 BRPI0519096-7A BRPI0519096A BRPI0519096A2 BR PI0519096 A2 BRPI0519096 A2 BR PI0519096A2 BR PI0519096 A BRPI0519096 A BR PI0519096A BR PI0519096 A2 BRPI0519096 A2 BR PI0519096A2
Authority
BR
Brazil
Prior art keywords
protein
receptor
precursor
diagnosing
polypeptide
Prior art date
Application number
BRPI0519096-7A
Other languages
English (en)
Inventor
S Ananth Karumanchi
Vikas P Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of BRPI0519096A2 publication Critical patent/BRPI0519096A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/321Arterial hypertension
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

ÁCIDOS NUCLÉICOS E POLIPEPTÍDEOS éTEIS PARA O DIAGNàSTICO E TRATAMENTO DE COMPLICAÇÕES NA GRAVIDEZ. A presente invenção refere-se a métodos para o diagnóstico e tratamento de distúrbios hipertensivos relacionados à gravidez que incluem o uso de um polipeptídeo ou um ácido nucléico que codifica um polipeptídeo selecionado dos seguintes: proteína relacionada à folistatina, interleucina 8, inibina A, VEGF-C, angiogenina, beta-fertilina, proteína hipotética, proteína secretada por receptor similar à lg associada a leucócito, proteína de diferenciação de eritróide, fator inibidor de adipogênese, proteína de ligação de fator de liberação de corticotropina, alfa-1 antiquimotripsina, proteina-5 de ligação de fator de crescimento similar à insulina, CD33L, fator 1 similar a receptor de citocina, fator de crescimento endotelial derivado de plaqueta, lisil hidrolase isoforma 2, precursor de estaniocalcina, proteína frizzled. relacionada secretada, galectina-3, esperminina oxidase, polipeptídeo B28 da família 2 de UDP glicosiltransferase, receptor de tirosina quinase neurotrófica, endopeptidase neutral, subunidade 2 reguladora de CDC28 proteína quinase, beta-glicosidase, alfa defensina, ADAM-TS3, precursor de colecisto- quinina, precursor de alfa-quimioatrativo de célula T estimulado por interferon, azurocidina, lanosterol sintase, serina proteína quinase dependente de cálcio/calmodulina, transcrito H unido alternativamente a receptor de estrogênio, receptor 1 de quimiocina (motivo CX3C), proteína 1 relacionada à tirosinase, hidróxi-delta-5-esteróide desidrogenase, diid ropiramidinase-similar- 4, e família-11 de citocromo P450.
BRPI0519096-7A 2004-12-15 2005-12-15 Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez BRPI0519096A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63627504P 2004-12-15 2004-12-15
PCT/US2005/045805 WO2007053161A2 (en) 2004-12-15 2005-12-15 Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy

Publications (1)

Publication Number Publication Date
BRPI0519096A2 true BRPI0519096A2 (pt) 2008-12-23

Family

ID=38006337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519096-7A BRPI0519096A2 (pt) 2004-12-15 2005-12-15 Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez

Country Status (11)

Country Link
US (1) US7955805B2 (pt)
EP (1) EP1839057B1 (pt)
JP (1) JP2008523816A (pt)
KR (1) KR20070092737A (pt)
CN (1) CN101299962A (pt)
AT (1) ATE478602T1 (pt)
AU (1) AU2005337873A1 (pt)
BR (1) BRPI0519096A2 (pt)
CA (1) CA2591142A1 (pt)
DE (1) DE602005023216D1 (pt)
WO (1) WO2007053161A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060067937A1 (en) 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
ES2475975T3 (es) 2004-12-21 2014-07-11 Yale University Diagnóstico de la preeclampsia
US7230561B2 (en) * 2005-01-27 2007-06-12 Micron Technology, Inc. Programmable integrating ramp generator and method of operating the same
US20060257901A1 (en) * 2005-03-24 2006-11-16 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
EP2102228A4 (en) * 2005-09-15 2011-06-01 Limited Dia-Mab METHOD FOR DIAGNOSIS OF PREECLAMPSIA
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
EP2126564B1 (en) * 2007-01-25 2012-10-03 Crc For Asthma And Airways Ltd Method of diagnosis
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
EP2037278A1 (en) * 2007-09-11 2009-03-18 F.Hoffmann-La Roche Ag Vascular markers in the remodelling of cardiac injury
WO2010033553A2 (en) * 2008-09-16 2010-03-25 University Of Florida Research Foundation Inc. Gene expression related to preeclampsia
CN104777308B (zh) 2008-10-31 2017-04-12 耶鲁大学 先兆子痫检测和治疗的方法和组合物
JP5524241B2 (ja) * 2009-01-28 2014-06-18 インダストリアル テクノロジー リサーチ インスティテュート 腎症と関連するバイオマーカー
WO2012048082A2 (en) * 2010-10-07 2012-04-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3336552A3 (en) * 2010-11-29 2018-07-25 Mote Marine Laboratory, Inc. Fish sexual characteristic determination using peptide hormones
CN102192987B (zh) * 2011-02-25 2014-04-02 复旦大学附属上海市第五人民医院 一种用于妊娠高血压疾病诊断的试剂盒
KR101114446B1 (ko) * 2011-02-25 2012-02-24 건국대학교 산학협력단 프로테오믹스기법을 이용한 임신중독 특이 표지 단백질 및 진단방법
ES2614059T3 (es) 2011-03-17 2017-05-29 Cedars-Sinai Medical Center Biomarcador de diagnóstico para predecir las mujeres en riesgo de parto prematuro
KR102200063B1 (ko) * 2011-11-30 2021-01-07 에이전시 포 사이언스, 테크놀로지 앤드 리서치 생물학적 모니터링을 위한 gm1 갱글리오사이드와 아넥신 ⅴ 마이크로입자 폴리펩타이드 비율
US20130344517A1 (en) * 2012-01-06 2013-12-26 Bg Medicine, Inc. Use of galectin-3 for risk assessment and detection of preeclampsia and related conditions
CN104634982B (zh) * 2013-11-06 2016-08-17 中国科学院上海生命科学研究院 Vegf-c在制备败血症及重症细菌感染诊断试剂中的用途
CN103760340B (zh) * 2014-01-28 2016-11-23 成都创宜生物科技有限公司 以flrg作为标志物制备检测工具的应用及检测工具
CA3157573C (en) 2014-04-10 2025-11-18 Yale University METHODS AND COMPOSITIONS FOR DETECTING MISFOLDED PROTEINS
US20160130553A1 (en) 2014-05-15 2016-05-12 Kellbenx Incorporated PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING
US12202890B1 (en) 2014-11-07 2025-01-21 Kellbenx Incorporated Antibodies for detection and enrichment of fetal cells and their use
EP3311158B1 (en) 2015-06-19 2023-08-30 Sera Prognostics, Inc. Biomarker pairs for predicting preterm birth
CN106771266A (zh) * 2017-01-12 2017-05-31 广州市丰华生物工程有限公司 抑制素a定量检测试剂盒及其制备方法
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α1−アンチキモトリプシンを含むバイオマーカー
US12436155B2 (en) * 2020-04-16 2025-10-07 Kalia Health, Inc. Preeclampsia screening device and methods measuring activin and/or inhibin A
CN111951969A (zh) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Hbp在高危妊娠预测中的应用
CN114075281B (zh) * 2021-11-16 2023-04-18 福州迈新生物技术开发有限公司 抗Inhibin-α蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5543138A (en) 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9512994D0 (en) 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
EP0938505B1 (en) 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
US6620590B2 (en) * 1996-07-11 2003-09-16 Isis Innovation Limited Diagnosis of pre-eclampsia
CA2275708A1 (en) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US6376199B1 (en) 1997-03-07 2002-04-23 The Hospital For Sick Children (Hsc) Methods to diagnose a required regulation of trophoblast invasion
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (en) 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
US6677300B1 (en) 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US6245577B1 (en) 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
EP1953244A1 (en) * 2002-01-09 2008-08-06 Nakamura, Yusuke Cancer profiles
US7407659B2 (en) * 2002-07-19 2008-08-05 Beth Israel Deaconess Medical Center Methods of diagnosing pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
ATE533857T1 (de) * 2003-01-17 2011-12-15 Univ Hong Kong Chinese Zirkulierende mrna als diagnostische marker für erkankungen die mit einer schwangerschaft zusammenhängen
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
DE10333105B3 (de) * 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
US7323346B2 (en) 2003-08-14 2008-01-29 The General Hospital Corporation Screening for gestational disorders
JP4568282B2 (ja) 2003-09-23 2010-10-27 ザ ジェネラル ホスピタル コーポレイション 妊娠性疾患のスクリーニング
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US20060067937A1 (en) 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
ES2475975T3 (es) 2004-12-21 2014-07-11 Yale University Diagnóstico de la preeclampsia
CN101517078A (zh) 2006-05-31 2009-08-26 貝丝以色列女执事医疗中心 诊断和治疗妊娠并发症的方法

Also Published As

Publication number Publication date
AU2005337873A1 (en) 2007-05-10
WO2007053161A3 (en) 2007-11-29
US20060166277A1 (en) 2006-07-27
CN101299962A (zh) 2008-11-05
CA2591142A1 (en) 2007-05-10
ATE478602T1 (de) 2010-09-15
EP1839057A2 (en) 2007-10-03
EP1839057A4 (en) 2008-12-31
KR20070092737A (ko) 2007-09-13
JP2008523816A (ja) 2008-07-10
DE602005023216D1 (de) 2010-10-07
US7955805B2 (en) 2011-06-07
EP1839057B1 (en) 2010-08-25
WO2007053161A2 (en) 2007-05-10
HK1115286A1 (en) 2008-11-28

Similar Documents

Publication Publication Date Title
BRPI0519096A2 (pt) Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
JP2008523816A5 (pt)
Ambekar et al. Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development
Pollheimer et al. Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast
Kobayashi et al. The ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian endometriosis
Molyneux et al. β1, 4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells
Sen et al. Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis
WO2022159520A3 (en) Methods for biomolecule quantitation
Taube et al. Foxa1 functions as a pioneer transcription factor at transposable elements to activate Afp during differentiation of embryonic stem cells
Vogt et al. ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth
Wolf et al. Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells
Xu et al. Expression of TGF-β signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells
Bumke et al. Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study
Zhao et al. Bone morphogenetic protein 2 promotes human trophoblast cell invasion and endothelial‐like tube formation through ID1‐mediated upregulation of IGF binding protein‐3
Despres et al. Replicative senescence of human dermal fibroblasts affects structural and functional aspects of the Golgi apparatus
Brkić et al. Differential role of Smad2 and Smad3 in the acquisition of an endovascular trophoblast-like phenotype and preeclampsia
Nagashima et al. Hepatocyte growth factor (HGF), HGF activator, and c-Met in synovial tissues in rheumatoid arthritis and osteoarthritis.
Xu et al. Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells
US20120329886A1 (en) Use of periostin as a novel biomarker
Jemelkova et al. GalNAc-T14 may contribute to production of galactose-deficient immunoglobulin A1, the main autoantigen in IgA nephropathy
KR102438838B1 (ko) 류마티스 관절염 진단용 바이오마커
DE69633913D1 (de) Schnelltest zur bestimmung der mange funktionell inactiver gene in einer für diegenetherapie bestimmten vektorpräparation
Lokshin et al. Transcriptional regulation by p53 and p73
Lee et al. AIMP1/p43 downregulates TGF-β signaling via stabilization of smurf2
Liu et al. Endothelin-1 stimulates human trophoblast cell migration through Cdc42 activation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2202 DE 19/03/2013.